Macrogen Inc (038290 ፦ ) የአክሲዮን ዋጋ እና ዜና

(KRW)	ማርች 2024	ከዓመት ዓመት ለውጥ
ገቢ	31.64 ቢ	-5.37%
የሥራ ወጪ	13.66 ቢ	21.31%
የተጣራ ገቢ	-2.15 ቢ	-268.88%
የተጣራ የትርፍ ክልል	-6.80	-278.48%
ገቢ በሼር	—	—
EBITDA	1.56 ቢ	-56.71%
ውጤታማ የግብር ተመን	6.47%	—

ቀሪ ሒሳብ ሉሆች

አጠቃላይ ንብረቶች

አጠቃላይ ተጠያቂነቶች

(KRW)	ማርች 2024	ከዓመት ዓመት ለውጥ
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ	21.92 ቢ	-46.62%
አጠቃላይ ንብረቶች	262.58 ቢ	-5.05%
አጠቃላይ ተጠያቂነቶች	106.93 ቢ	8.46%
አጠቃላይ እሴት	155.65 ቢ	—
የሼሮቹ ብዛት	9.98 ሚ	—
የገበያ ዋጋ እና የተገለጸ ዋጋ	1.17	—
የእሴቶች ተመላሽ	-1.20%	—
የካፒታል ተመላሽ	-1.50%	—

የገንዘብ ፍሰት

የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ

(KRW)	ማርች 2024	ከዓመት ዓመት ለውጥ
የተጣራ ገቢ	-2.15 ቢ	-268.88%
ከክወናዎች የተገኘ ጥሬ ገንዘብ	-3.64 ቢ	36.93%
ገንዘብ ከኢንቨስትመንት	-6.22 ቢ	-937.19%
ገንዘብ ከፋይናንስ	4.41 ቢ	329.27%
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ	-4.63 ቢ	41.55%
ነፃ የገንዘብ ፍሰት	-18.33 ቢ	-850.95%

ስለ

Macrogen, Inc. is a South Korean public biotechnology company. The company's headquarters are located in Seoul. The company was founded in 1997 by Jeong-sun Seo, a professor at Seoul National University. It was venture capital-backed until its initial public offering and subsequent listing on the KOSDAQ market in 2000, making it the first Korean biotechnology firm to raise funds through an IPO. The company announced plans in 2010 to map the "Korean genome" based on the notion that United States-backed genome mapping efforts up to that time were representative of the "Caucasian genome" rather than the "Human genome" as claimed. By 2015, the company was described by one news outlet as "a global leader in personalized genomic medicine". Wikipedia

ዋና ሥራ አስፈጻሚ

Changhoon Kim

የተመሰረተው

5 ጁን 1997

ድህረገፅ

macrogen.com

ሠራተኞች

532